Larazotide (AT-1001)
GUT HEALINGQuick Specifications
| Vial Size | 10MG (10 TABLETS x 1MG) |
|---|---|
| BAC Water | N/A — ORAL TABLETS |
| Amount Per Unit | 1MG PER TABLET |
| Recommended Dose | 0.25MG TO 1MG (0.25 TO 1 TABLET PER DOSE, THREE TIMES DAILY) |
| Frequency | THREE TIMES DAILY, 30 MINUTES BEFORE MEALS |
| Injection Type | ORAL TABLETS |
| Timing | Take 30 minutes before each meal for maximum tight junction protection during food antigen exposure. Phase 2 celiac trials used 0.25mg, 1mg, or 2mg TID — current community protocols use 0.5-1mg TID. Part of the Gut Healing Stack with KPV and BPC-157 Oral Tablets. Can be run continuously or in 4-6 week cycles. |
Research Overview
Larazotide acetate (AT-1001) is a synthetic 8-amino acid peptide derived from Vibrio cholerae zona occludens toxin (ZOT) that acts as a tight junction regulator — the most specific peptide tool available for intestinal barrier research. Larazotide's mechanism is precise: it blocks the action of zonulin — the endogenous protein that triggers tight junction disassembly and increases intestinal permeability ('leaky gut') — by competitively inhibiting zonulin receptor binding on intestinal epithelial cells. Unlike compounds that repair existing tissue damage, Larazotide acts at the structural barrier level, preventing the paracellular leakage of antigens, pathogens, and toxins that drives gut-systemic inflammation. Phase 2 clinical trials demonstrated significant reduction in intestinal permeability markers, anti-gliadin antibody levels, and gastrointestinal symptoms in celiac disease patients. Separate trials in non-celiac IBD populations showed favorable safety and symptom improvement. Larazotide is the structural component of the Gut Healing Stack, where it works alongside KPV (melanocortin receptor-mediated mucosal anti-inflammation) and BPC-157 Oral Tablets (VEGFR2-driven tissue repair) to address all three foundational layers of gut dysfunction simultaneously. All-oral administration targets the intestinal lining directly. For research and educational purposes only.
Commonly Studied With
These peptides are frequently researched alongside Larazotide (AT-1001): 10mg due to complementary mechanisms:
For research-grade Larazotide with third-party Certificate of Analysis documentation, Peptide Hub recommends Apollo Peptide Sciences. Apollo Peptide Sciences carries Larazotide (AT-1001) in their gut health catalog. Affiliate disclosure: we may earn a commission on purchases through this link.
Larazotide (AT-1001): 10mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: 0.25MG TO 1MG (0.25 TO 1 TABLET PER DOSE, THREE TIMES DAILY)